Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2014 5
2015 5
2016 7
2017 11
2018 3
2019 5
2020 3
2021 5
2022 8
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer.
Malchers F, Nogova L, van Attekum MH, Maas L, Brägelmann J, Bartenhagen C, Girard L, Bosco G, Dahmen I, Michels S, Weeden CE, Scheel AH, Meder L, Golfmann K, Schuldt P, Siemanowski J, Rehker J, Merkelbach-Bruse S, Menon R, Gautschi O, Heuckmann JM, Brambilla E, Asselin-Labat ML, Persigehl T, Minna JD, Walczak H, Ullrich RT, Fischer M, Reinhardt HC, Wolf J, Büttner R, Peifer M, George J, Thomas RK. Malchers F, et al. Among authors: bragelmann j. J Clin Invest. 2023 Nov 1;133(21):e170217. doi: 10.1172/JCI170217. J Clin Invest. 2023. PMID: 37606995 Free PMC article.
Clinicopathologic and molecular characteristics of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients.
Glaser M, Rasokat A, Prang D, Nogova L, Wömpner C, Schmitz J, Bitter E, Terjung I, Eisert A, Fischer R, John F, von Levetzow C, Michels S, Riedel R, Ruge L, Scharpenseel H, Siebolts U, Merkelbach-Bruse S, Buettner R, Brägelmann J, Wolf J, Scheffler M. Glaser M, et al. Among authors: bragelmann j. Lung Cancer. 2023 Oct;184:107344. doi: 10.1016/j.lungcan.2023.107344. Epub 2023 Aug 12. Lung Cancer. 2023. PMID: 37579577 Free article.
KEAP1/NFE2L2 Pathway Signature Outperforms KEAP1/NFE2L2 Mutation Status and Reveals Alternative Pathway-Activating Mutations in NSCLC.
Arolt C, Dugan M, Wild R, Richartz V, Holz B, Scheel AH, Brägelmann J, Wagener-Ryczek S, Merkelbach-Bruse S, Wolf J, Buettner R, Catanzariti L, Scheffler M, Hillmer AM. Arolt C, et al. Among authors: bragelmann j. J Thorac Oncol. 2023 Nov;18(11):1550-1567. doi: 10.1016/j.jtho.2023.07.016. Epub 2023 Jul 18. J Thorac Oncol. 2023. PMID: 37473958 Free article.
Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung Cancer.
Müller N, Lorenz C, Ostendorp J, Heisel FS, Friese UP, Cartolano M, Plenker D, Tumbrink H, Heimsoeth A, Baedeker P, Weiss J, Ortiz-Cuaran S, Büttner R, Peifer M, Thomas RK, Sos ML, Berg J, Brägelmann J. Müller N, et al. Among authors: bragelmann j. Cancer Res. 2023 Aug 1;83(15):2471-2479. doi: 10.1158/0008-5472.CAN-22-2605. Cancer Res. 2023. PMID: 37289018
Elevated FSP1 protects KRAS-mutated cells from ferroptosis during tumor initiation.
Müller F, Lim JKM, Bebber CM, Seidel E, Tishina S, Dahlhaus A, Stroh J, Beck J, Yapici FI, Nakayama K, Torres Fernández L, Brägelmann J, Leprivier G, von Karstedt S. Müller F, et al. Among authors: bragelmann j. Cell Death Differ. 2023 Feb;30(2):442-456. doi: 10.1038/s41418-022-01096-8. Epub 2022 Nov 29. Cell Death Differ. 2023. PMID: 36443441 Free PMC article.
Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors.
Borchmann S, Selenz C, Lohmann M, Ludwig H, Gassa A, Brägelmann J, Lohneis P, Meder L, Mattlener J, Breid S, Nill M, Fassunke J, Wisdom AJ, Compes A, Gathof B, Alakus H, Kirsch D, Hekmat K, Büttner R, Reinhardt HC, Hallek M, Ullrich RT. Borchmann S, et al. Among authors: bragelmann j. J Immunother Cancer. 2022 Oct;10(10):e004781. doi: 10.1136/jitc-2022-004781. J Immunother Cancer. 2022. PMID: 36223955 Free PMC article.
Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing Inhibitors.
Lategahn J, Tumbrink HL, Schultz-Fademrecht C, Heimsoeth A, Werr L, Niggenaber J, Keul M, Parmaksiz F, Baumann M, Menninger S, Zent E, Landel I, Weisner J, Jeyakumar K, Heyden L, Russ N, Müller F, Lorenz C, Brägelmann J, Spille I, Grabe T, Müller MP, Heuckmann JM, Klebl BM, Nussbaumer P, Sos ML, Rauh D. Lategahn J, et al. Among authors: bragelmann j. J Med Chem. 2022 May 12;65(9):6643-6655. doi: 10.1021/acs.jmedchem.1c02080. Epub 2022 Apr 29. J Med Chem. 2022. PMID: 35486541
49 results